Navigation Links
Say Goodbye to Unwanted Love Handles: CoolSculpting by ZELTIQ™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction
Date:9/8/2010

PLEASANTON, Calif., Sept. 8 /PRNewswire/ -- Great news for men and women dealing with one of the most exercise and diet-resistant problem areas: "love handles." CoolSculpting™ is now cleared by the U.S. Food and Drug Administration (FDA) for the non-invasive reduction of fat. ZELTIQ™, a global medical device company, developed the procedure which delivers a non-invasive, safe, and clinically proven method for the selective reduction of "love handles" or flank.

(Photo:  http://photos.prnewswire.com/prnh/20100908/LA60996-a)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100908/LA60996-a)

(Photo:  http://photos.prnewswire.com/prnh/20100908/LA60996-b)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100908/LA60996-b)

(Photo:  http://photos.prnewswire.com/prnh/20100908/LA60996-c)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20100908/LA60996-c)

"There is a strong demand for non-invasive procedures that can address the concerns of people who are not considered overweight, but despite diet and exercise, have pockets of fat that bother them," said Dr. Jeffrey S. Dover, a board certified dermatologist, associate clinical professor of dermatology at Yale University School of Medicine, and co-director of SkinCare Physicians. "While traditional liposuction and laser liposuction are invasive surgical procedures that are designed for fat reduction, CoolSculpting is an exciting new approach that is non-invasive and has shown significant, durable, and reliable results in clinical studies for removing fat without the potential risks and downtime of invasive procedures."

CoolSculpting fills a previously unmet need in the medical aesthetic marketplace with a safe procedure cleared by the FDA that gently cools unwanted fat cells in the body to induce a natural, controlled elimination of fat cells. This reduces bulges in the treated area of the body. On average, each CoolSculpting procedure results in a 20% reduction of fat in the treated area, and patients can start to see results as soon as three weeks following treatment, with the most dramatic results occurring over a period of two to four months in most patients.

Unlike most other methods of fat reduction, CoolSculpting involves no needles, surgery or downtime. During the procedure, a non-invasive applicator delivers precisely controlled cooling to the treatment area to specifically target underlying fat, leaving surface skin tissue unaffected. Procedures last about one to two hours. Patients can have additional procedures for more pronounced effects if they desire.

Developed at the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston, the CoolSculpting breakthrough is based on extensive scientific research that demonstrates that fat cells are more susceptible to extreme cold and are selectively, painlessly, and permanently destroyed. This process is known as Cryolipolysis™ (cold lipolysis). Starting several weeks after the procedure, cooled fat cells begin a process called apoptosis (natural cell death) and begin to shrink and disappear. Comprehensive multi-center clinical studies submitted to the FDA validated that CoolSculpting kills fat cells in the area treated based on histological and ultrasound assessment.

The CoolSculpting procedure by ZELTIQ will be available through an elite network of CoolSculpting Centers across the U.S. starting immediately.  Consumers are urged to ask for CoolSculpting by name, for there are no comparable non-invasive alternatives.  Worldwide, more than 7,000 patients have already been treated.

The 'Skinny' on Fat Reduction

CoolSculpting by ZELTIQ is not intended as a weight-reduction program for overweight individuals. The best candidates for the CoolSculpting procedure are people near their ideal body weight who eat well and exercise regularly and have pockets of fat that have not responded to a healthy lifestyle. They are seeking long-lasting spot reduction for this specific area of fat, but they are not considering a surgical procedure with its inherent expense, downtime, and safety risks.

About ZELTIQ

Founded in 2005, ZELTIQ™ is a global medical device company that developed its patented, non-invasive, clinically proven procedure to selectively reduce fat.  The initial Cryolipolysis™ research and patents were originated at the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston, a teaching affiliate of Harvard Medical School, by Dr. Dieter Manstein and Dr. R. Rox Anderson. ZELTIQ has exclusive rights to this innovative, "cool" approach to permanently removing fat. CoolSculpting™ is cleared in the United States, Canada, the European Union, and other international markets for non-invasive fat layer reduction. Physicians and patients are encouraged to visit www.coolsculpting.com to receive additional information and announcements about ZELTIQ.


'/>"/>
SOURCE ZELTIQ
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Say Goodbye to Back Fat Rolls
2. Watsons Generic Yasmin® Receives FDA Approval
3. Shanghai SynTheAll Pharmaceuticals Co., Ltd. (STA) Receives ISO 14001 Certification
4. Celsion Receives SBIR Grant To Expand Its Technology Platform
5. Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System
6. K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
7. Actavis Receives FDA Approval of Atomoxetine HCl Capsules
8. Abbott Receives FDA Approval for First Automated Molecular Test for Assessing Hepatitis B Treatment
9. Amedica® Receives Patent for Knee Prosthesis With Monoblock Silicon Nitride Ceramic Tibial Component
10. Bionovo Receives Positive Guidance from FDA on Menerba®
11. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile app ... struggle to reverse the tide of prescription drug addiction. The ... their medicine intake and stepping down their dosage in a ... launch in December 2017; the first 100,000 people to sign ... at http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):